Novartis heralds a PhIII success for secondary progressive MS drug
Novartis has scored a success for a Phase III study of BAF312 (siponimod), reducing the risk of crippling CNS damage in secondary progressive multiple sclerosis. The drug is in a class of S1P receptor modulators that has attracted considerable attention in the field.
Investigators set out to see if the drug could hit its primary endpoint: reducing the risk of three-month confirmed disability progression versus placebo. In secondary progressive MS patients continue to worsen independent of the periodic flare ups that afflict patients with relapsing-remitting MS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.